Licensing, Mergers & Acquisitions

Case Study

Bellus Health: BLUS

• Geller Biopharm was retained to outlicense KIACTA, a Ph III asset for an orphan renal disorder
• Initial work entailed
  • Positioning: focusing on orphan disease and creation of new markets
  • Presentation: building investor appropriate materials, and supporting marketing studies
• Arranged introductions with 80+ US, EU and Asian pharmaceutical and biotech companies in the orphan, renal, and autoimmune space and brought management team to major US and EU conferences
• Secured over 25 CDA's and led potential partners through online data rooms, onsite due diligence sessions and eventual term sheet negotiations with several companies
  • One of the largest pharmaceutical companies in the world remarked that Geller Biopharm had conducted the most thorough and well organized on-site diligence session their team has ever experienced
  • The testimonial may not be representative of the experience of other companies and is no guarantee of future performance or success
• Brokered unique transaction in which Celtic Therapeutics paid an upfront fee to Bellus, covered all trial and filing costs to bring KIACTA to the market, with Bellus retaining 50% rights to the product